Discovering and developing innovative therapies for patients with challenging brain and nervous system disorders.

Producing therapies with novel chemistry that modulate NMDA receptors, which are vital to normal brain physiology, and restore normal balance in the brain & CNS

Advancing development candidates across post-traumatic stress disorder, cognitive impairment, and opioid use disorder

Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate — rather than block or over-activate — NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. We believe leveraging the therapeutic advantages of this differentiated mechanism will drive a paradigm shift in the treatment of numerous disorders of the brain and nervous system.

Our current clinical development programs span cognitive impairment, post-traumatic stress disorder, and opioid use disorder. We are also developing a robust library of preclinical candidates.